What Are the Structural Drivers of Rising Development Costs?
Many of the factors contributing to these mounting costs are less a sign of organisational inefficiency or mismanagement than a reflection of the evolving state of scientific regulation. With straightforward treatment pathways becoming fewer and further between, the industry has been pushed towards more challenging therapeutic areas like oncology or neurodegenerative diseases. This often requires more sophisticated biomarker strategies, adaptive trial designs and extended follow-up periods to demonstrate clinically meaningful benefits, once again increasing the financial burden [2] on pharma organisations.
As the treatments themselves become more complex, the clinical trial process has developed similarly, with the average Phase III trial now enrolling over 800 patients across multiple countries and requiring 18–24 months to complete recruitment. Protocol complexity has also increased by approximately 50% over the past decade, leading to corresponding rises in site burden, patient dropout rates and monitoring costs. And although traditional monitoring expenses are increasingly offset by centralised processes and technological integration, these measures have yet to fully ease the financial burden.
The industry’s shift toward precision medicine and targeted therapies has introduced further complexity to the development process; although these more bespoke medicines often need a smaller patient population to demonstrate efficacy, they require a more sophisticated trial infrastructure. This is a particularly challenging dynamic for rare disease drug development, where ultra-small patient populations and limited natural history data complicate how clinical trials are designed.
Regulatory requirements have also evolved considerably over recent decades, with authorities demanding more comprehensive safety databases, mechanistic understanding of drug action and evidence of clinical benefit beyond surrogate endpoints. Guidelines from the International Council for Harmonisation (ICH) have established minimum standards for drug development, but individual regulatory authorities often impose additional requirements which reflect regional priorities or historical precedents.
Optimising Costs Via Strategic Partnership Models
Partnerships have long provided a way for the pharma industry to access specialised capabilities, share development risks and optimise resource allocation across portfolios. Seeking new approaches to collaboration has enabled pharmaceutical companies to maintain a focus on their core competencies whilst accessing external capabilities that would be inefficient to develop internally. In particular, CRO partnerships [3] have evolved into a support system for pharma companies looking to scale up development or move into new therapeutic areas. Meanwhile, functional service provider (FSP) models provide access to dedicated CRO personnel who can be integrated into in-house teams.
Another way for organisations to find a reliable stream of new talent and ideas is through partnering with research institutions [4] and teaching hospitals. These collaborations often focus on early-stage research activities including target identification, biomarker discovery, and proof-of-concept studies. This is where academic investigators can provide unique expertise and infrastructural support, particularly in more sophisticated objectives such as intellectual property frameworks, publication policies and governance structures.
The Emerging Open Innovation Ecosystem
The pharmaceutical industry has progressively embraced open innovation principles that challenge traditional vertically integrated models of R&D. Open innovation recognises that there are valuable scientific insights and technological capabilities to be gained outside of organisational boundaries. This creates an imperative to access external innovation through licensing, acquisitions and collaborative research arrangements, a philosophical shift which has spawned diverse models of innovation including innovation hubs, accelerator programmes and venture creation studios.
Biotech startups represent particularly attractive innovation partners, often pursuing novel mechanisms, unconventional therapeutic approaches, or underserved patient populations previously deprioritised by the pharmaceutical establishment. The attraction to pharma sponsors is clear, as these kinds of organisations typically operate with lean cost structures, entrepreneurial cultures, and a more agile approach to strategy. However, the key is to not only identify the right collaborators early in their development, but also to ensure that these early-stage assets are valued appropriately, without putting ongoing development costs in jeopardy.
The introduction of AI and machine learning have also allowed tech platforms to become more efficient by running multiple programmes at once, as opposed to optimising assets one at a time. These technologies are often applied in the drug discovery phase for target identification, compound optimisation and patient stratification, with a view to speeding up timelines and improving success rates. In the wake of the COVID-19 pandemic, decentralised and hybrid clinical trial models [5] also gained traction, helping them reduce burden on individual sites, and allowing for remote patient monitoring. These approaches can reduce trial costs by between 20 and 30%, thanks to their broader geographic reach, which has a positive impact on patient recruitment and retention.
